CRISPR Therapeutics — Blitz Index 48 (C)
CASGEVY is approved and ramping — but product revenue is $0.
Confidence: High · Category: frontier
Score breakdown
| Section | Score | Detail |
|---|---|---|
| A · Speed | 14 / 25 | CASGEVY quarterly revenue $76M (+78% QoQ, +151% YoY) — accelerating commercial ramp; but all company revenue is milestones and grants |
| B · Moat | 24 / 60 | World's first CRISPR therapy — category-definer position; 39-country approvals; in vivo pipeline entering clinic |
| C · Creative destruction | 12 / 15 | Chronic dosing → one-time cure — the paradigm shift is the score's backbone |
| D · BlitzFailing | −2 | 100% Vertex dependence for manufacturing and commercialization; $0 own product revenue — collaboration-expense net −$213.5M/year |
Radar axes (0–100): Moat 40 · Speed 56 · Creative 80.
Watch item
Gates: G1 ✓ (borderline) · G2 ✓ (declared basis). 17 points below the threshold — the science is historic; the business isn't yet.
Strengths
- CASGEVY quarterly revenue $76M (+78% QoQ, +151% YoY) — accelerating ramp
- 39-country approvals + FDA label to age 2+ + German reimbursement — access widening
- In vivo pipeline entering clinic (CTX310 in NEJM, CTX340/460 Phase 1)
- $2.36B cash, ~6-year runway — time is ample
Concerns
- $0 own product revenue — collaboration-expense net −$213.5M/year while commercializing
- 100% Vertex dependence — manufacturing and commercialization led by the partner
- CRISPR IP landscape highly dynamic — patent litigation risk
- $2.2M upfront per patient vs lifetime payer benefit — adoption bottleneck
More Frontier companies
Other Frontier names on the Blitz Index, highest score first: Rocket Lab (62/B), Tesla (62/B), Insulet (57/C).
Next earnings
Nov 2026 · Unconfirmed
Coverage
CRISPR Therapeutics AG · Q3 2026 due Nov 2026 (unconfirmed) · Score 48 · Grade C
Embed this score
Copy the HTML below to show this score on your site. The badge links back to this page and updates automatically when the score changes.
Preview:
BlitzLab scores businesses against a scholar’s standard — not investment advice. No price targets, no buy/sell recommendations. Figures are from SEC filings (XBRL) as labeled in the source scorecard.